Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
pneumococcal vaccine
Pharma
FDA grants Pfizer's Prevnar 20 priority review for pediatric use
The FDA has designated Pfizer's next-generation pneumococcal vaccine Prevnar 20 for priority review in children aged 6 weeks through 17 years.
Kevin Dunleavy
Jan 6, 2023 10:20am
Pfizer shows key data, setting up pediatric nod for Prevnar 20
Aug 12, 2022 10:50am
Merck's Prevnar rival snags key pediatric nod
Jun 22, 2022 6:45am
At Pfizer, Anderson takes over for Jansen as vaccine R&D chief
Jun 2, 2022 1:48pm
FDA extends review of Merck's Vaxneuvance to July
Apr 1, 2022 9:52am
Sanofi aims to double vaccine sales by 2030
Dec 1, 2021 1:29pm
